Latest news with #COVID-related
Malaysian Reserve
3 hours ago
- Business
- Malaysian Reserve
WST Deadline: WST Investors Have Opportunity to West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
NEW YORK, June 20, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline. So what: If you purchased West Pharmaceutical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the West Pharmaceutical class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the West Pharmaceutical class action, go to Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@
Hindustan Times
3 days ago
- Health
- Hindustan Times
Ludhiana district logs 8 new Covid cases
Ludhiana reported eight fresh COVID-19 cases on Tuesday, bringing the total number of active cases in the district to 29. The new cases include six men aged between 23 and 82, and two women aged 25 and 52. Out of these, six are from urban areas while two belong to rural parts of the district. The total reported cases so far stand at 55, with 24 patients having successfully completed home quarantine. Two COVID-related deaths have also been recorded. According to Dr Sheetal Narang, epidemiologist at the civil hospital, four of the eight patients were asymptomatic, and only one of them reported a mild sore throat. She further added that except for one patient, all others were vaccinated, and one had even received a booster dose. 'Currently, only three patients are hospitalised, showing symptoms such as fever, cough, and cold,' she said. Health officials are urging the public to remain vigilant and follow safety protocols, especially as some new cases involve people with no symptoms at all. They advised citizens to wear masks in crowded or poorly ventilated areas and to isolate themselves and consult a nearby health centre if they experience any symptoms like fever, cough, or difficulty in breathing. People are also advised to maintain proper hand hygiene, avoid unnecessary gatherings, and ensure good ventilation in indoor spaces.
Sydney Morning Herald
3 days ago
- Business
- Sydney Morning Herald
Taxpayers fork out almost $500m to shield Metro Trains from pandemic fallout
Private company Metro Trains is receiving hundreds of millions of taxpayer dollars to offset lower passenger revenue, allowing the company to record bumper profits despite reduced patronage post-pandemic. Work-from-home habits have left an enduring dent in Melbourne's public transport usage and associated fare revenue, with train passenger numbers in the first three months of 2025 still 22 per cent below 2019 levels. Tram passenger numbers were down 20 per cent compared to 2019, while Melbourne's bus network patronage was down 6 per cent. Metro Trains reported 17.9 million passengers in March this year – 4.2 million fewer than in March 2019, representing a loss of about 137,000 passengers every day. But Metro – majority owned by Hong Kong's MTR Corporation – has largely escaped the financial impact of the passenger downturn due to contract provisions, which have set it up for 'strong profit results' until the contract ends in November 2027. The 2025/26 state budget, released last month, shows the Allan government will spend $489 million over the next four years to address 'COVID-19 impacts' on Metro train services, including offsetting 'lower revenue associated with changed travel patterns to maintain service delivery'. The COVID-related top-up will cost $176.1 million in the coming financial year, $182.1 million in 2026-27, $103.1 million in 2027-28 and $28.3 million in 2028-29. The $489 million package was announced as part of a budget straining under Victoria's record-high debt, forecast to hit $155.5 billion by the end of this month and $194 billion by mid-2029. The expense comes on top of previous 'reset payments' made to Metro and other transport operators since January 2022.
The Age
3 days ago
- Business
- The Age
Taxpayers fork out almost $500m to shield Metro Trains from pandemic fallout
Private company Metro Trains is receiving hundreds of millions of taxpayer dollars to offset lower passenger revenue, allowing the company to record bumper profits despite reduced patronage post-pandemic. Work-from-home habits have left an enduring dent in Melbourne's public transport usage and associated fare revenue, with train passenger numbers in the first three months of 2025 still 22 per cent below 2019 levels. Tram passenger numbers were down 20 per cent compared to 2019, while Melbourne's bus network patronage was down 6 per cent. Metro Trains reported 17.9 million passengers in March this year – 4.2 million fewer than in March 2019, representing a loss of about 137,000 passengers every day. But Metro – majority owned by Hong Kong's MTR Corporation – has largely escaped the financial impact of the passenger downturn due to contract provisions, which have set it up for 'strong profit results' until the contract ends in November 2027. The 2025/26 state budget, released last month, shows the Allan government will spend $489 million over the next four years to address 'COVID-19 impacts' on Metro train services, including offsetting 'lower revenue associated with changed travel patterns to maintain service delivery'. The COVID-related top-up will cost $176.1 million in the coming financial year, $182.1 million in 2026-27, $103.1 million in 2027-28 and $28.3 million in 2028-29. The $489 million package was announced as part of a budget straining under Victoria's record-high debt, forecast to hit $155.5 billion by the end of this month and $194 billion by mid-2029. The expense comes on top of previous 'reset payments' made to Metro and other transport operators since January 2022.
Time of India
3 days ago
- Health
- Time of India
153% Jump in COVID Searches Reveals India's Vigilance Amid New Wave Fears
New Delhi: As India witnesses a resurgence of COVID-19 cases—with active infections surpassing the 7,000 mark—new search data from local search engine Justdial, reveals a significant shift in public behaviour. COVID-related searches spiked by 153 per cent nationwide between April and May 2025, reflecting a palpable increase in public concern and preparedness across cities. Among the top trends were an 8x increase in searches for government testing centres, a 77 per cent rise in insurance-related queries, and a threefold jump in vaccine centre lookups under the Pradhan Mantri Jan Arogya Yojana (PM-JAY). The capital city Delhi has emerged as the most proactive, with a 140 per cent rise in overall COVID-related searches and a 15x surge in government testing centre queries. According to Justdial's report, the renewed public interest spans both metros and smaller cities, indicating broader health awareness. In Mumbai, searches for private testing rose alongside a 26 per cent increase in insurance-related lookups. Kerala, meanwhile, recorded an 84 per cent surge in insurance searches, the highest in the country. ETHealthworld's Rashmi Kaur spoke to experts from healthcare facilities to understand on how they view the public's proactive approach. 'Yes, we are witnessing huge spikes in footfalls for COVID testing, especially for travelers and those with mild symptoms,' confirmed Dr. Diksha Goyal, Senior Consultant – Internal Medicine at Marengo Asia Hospitals, Gurugram. 'We've streamlined testing logistics, stocked up on kits and PPE, and trained our staff to handle the surge efficiently. Online bookings and electronic reporting are helping us reduce crowding and waiting times.' Dr. Deepak Sanghavi, Vice President of Operations at Agilus Diagnostics, emphasized that the rising interest in testing is not just reactive but also preventive. 'While there's no panic, people are clearly more alert. We're seeing increased demand from symptomatic individuals, their contacts, and even post-infection follow-ups—many opting for home sample collection,' he said. While numbers are rising, doctors believe the clinical picture is changing. 'Many cases are now presenting with milder, influenza-like symptoms such as nasal congestion, sore throat, and fatigue,' said Dr. Goyal. 'Severe respiratory distress is rare, particularly in vaccinated individuals. However, early detection remains tricky, as the symptoms are more insidious. High-risk groups still need close monitoring and timely care.' Dr. Sanghavi echoed, 'This is not the same panic-driven atmosphere we saw during earlier waves. Public behaviour now shows a desire for early awareness and informed action. That's a good sign.' Demand for Booster shots With immunity waning and infection trends climbing, public interest in booster doses is seeing a revival. 'There's a clear uptick in people—especially seniors—seeking booster shots. While national advisories are awaited, state-level initiatives are encouraging precautionary vaccination for high-risk groups,' said Dr. Goyal. What sets this surge apart from earlier waves is the public's proactive response—seeking out information, verifying coverage options, and opting for safe testing methods like home collection. 'Healthcare providers and diagnostics labs are more prepared than ever before,' said Dr. Sanghavi. 'India's healthcare infrastructure, bolstered by earlier experiences, is well-equipped to manage this rise efficiently.' While health authorities monitor the evolving situation, experts agree that public vigilance, timely testing, accurate information, and vaccinations remain the most effective tools in preventing another full-blown crisis.
